Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Across the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, Lillys investigational triple agonist delivered up to 22.6% mean weight loss at 80 weeks, alongside robust glycaemic improvement and broad cardiometabolic risk-factor reductions
and GHRP-2, a strong growth hormone secretagogue
By targeting both pathways, tirzepatide offers a dual-action mechanism that reduces appetite and improves insulin sensitivity
et al
monitor blood sugar closely in the first few weeks and report any episodes to your provider Gallbladder-related symptoms rapid weight change in either direction can increase risk
US$ 24.75
US$ 29.97
US$ 25.19
